As part of the visit of the Delpharm factory in Saint-Rémy-sur-Avre, Emmanuel Macron has advocated for the use of AstraZeneca vaccine in France. “I trust the health authorities saying the AstraZeneca vaccine is recommended and must be used in compliance with the age recommendations”, the French President said this April 9. “It is not used in younger people, but still in the oldest ones […], especially when they have a risk factor”, he added.
Statements made as 71% of the French are said not to trust the AstraZeneca vaccine – according to an Odoxa-Backbone Consulting for Le Figaro released on April 8. For the record, several cases of thrombosis related to the AstraZeneca vaccine have been reported in France.
AstraZeneca vaccine: three new cases of thrombosis, and two deaths reported in France
According to the Agence du Médicament – Medicines Agency (ANSM) – three new cases of thrombosis related to AstraZeneca vaccine, including two more deaths, have been reported between March 19 and 25 in France.
AstraZeneca: thromboses considered as ”rare side effects” of the vaccine, EMA says
After the Medicines Agency confirmed the existence of a "rare" risk of atypical thrombosis, this Tuesday April 6, the European Medicines Agency declares there is indeed a link between the vaccine and the creation of blood clots. The day after, on Wednesday April 7, the European regulator announced in a press brief they list blood clots as one of vaccine rare adverse effects.
This Friday, the Haute Autorité de Santé shared their latest recommendations as for the use of the AstraZeneca vaccine. Therefore, as for people under 55 who have been a first dose of the AstraZeneca vaccine, they are recommended to get another vaccine for the second dose.
The Haute Autorité de Santé also recommends not to used the AstraZeneca vaccine in some overseas territories and Moselle; areas where the “South-African” variant spreads the most.